XML 83 R72.htm IDEA: XBRL DOCUMENT
v3.25.2

Revenue recognition - Collaboration and Royalty Revenue (Details) $ in Thousands | 1 Months Ended | 3 Months Ended | 6 Months Ended |  |
--- | --- | --- | --- | --- | ---
Jan. 31, 2025 USD ($) | Jun. 30, 2025 USD ($) | Jun. 30, 2024 USD ($) | Jun. 30, 2025 USD ($) product | Jun. 30, 2024 USD ($) | Dec. 31, 2024 USD ($) | Nov. 30, 2011 USD ($)
Revenue recognition |  |  |  |  |  |  |
Number of approved products | product |  |  |  | 2 |  |  |
Remaining potential milestones that can be achieved |  |  |  |  |  | $ 150,000 |
Revenue |  | $ 178,875 | $ 186,704 | $ 1,354,971 | $ 396,822 |  |
Deferred revenue |  | 9,760 |  | 9,760 |  | $ 5,505 |
Collaboration and license revenue |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |
Revenue |  | 2,941 |  | 989,172 |  |  |
Royalty revenue |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |
Revenue |  | 57,605 | 53,183 | $ 94,044 | 84,337 |  |
SMA License Agreement |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |
Number of approved products | product |  |  |  | 1 |  |  |
SMA License Agreement | Collaboration and license revenue |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |
Revenue |  |  | 0 |  | 0 |  |
SMA License Agreement | Royalty revenue |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |
Revenue |  | 57,600 | $ 53,200 | $ 94,000 | $ 84,300 |  |
License and Collaboration Agreement |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |
Refund of revenue related to prior collaboration arrangements |  |  |  | 3,500 |  |  |
License and Collaboration Agreement | Novartis |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |
Cash proceeds from upfront payment on collaboration agreement | $ 1,000,000 |  |  |  |  |  |
Percentage share of the income (loss) generated on U.S. sales | 40.00% |  |  |  |  |  |
Deferred revenue |  | 7,300 |  | 7,300 |  |  |
License and Collaboration Agreement | Novartis | Collaboration and license revenue |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |
Revenue |  | 2,900 |  | 992,700 |  |  |
Research And Development Event Milestones | SMA License Agreement |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |
Remaining potential milestones that can be achieved |  | 0 |  | 0 |  |  |
Sales Milestones | SMA License Agreement |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |
Remaining potential milestones that can be achieved |  | $ 150,000 |  | $ 150,000 |  |  |
Maximum | License and Collaboration Agreement | Novartis |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |
Potential future proceeds contingent on achievement of developmental, regulatory and sales milestones and tiered royalties | $ 1,900,000 |  |  |  |  |  |
Maximum | Research And Development Event Milestones | SMA License Agreement |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |
Remaining potential milestones that can be achieved |  |  |  |  |  |  | $ 135,000
Maximum | Sales Milestones | SMA License Agreement |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |
Remaining potential milestones that can be achieved |  |  |  |  |  |  | $ 325,000

X
- Definition The amount of cash inflow from collaborative agreement that was received as an upfront payment upon closing. + References No definition available. + Details
Name: | ptct_CashProceedsCollaborativeAgreementUpfrontPayment
Namespace Prefix: | ptct_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of potential future proceeds which may be received contingent on achievement of specified developmental, regulatory and sales milestones and tiered royalties on ex-US sales. + References No definition available. + Details
Name: | ptct_ContingentFutureProceedsBasedOnAchievementOfDevelopmentalRegulatoryAndSalesMilestonesAndTieredRoyalties
Namespace Prefix: | ptct_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of refund of consideration received under prior collaboration arrangements. + References No definition available. + Details
Name: | ptct_ContractWithCustomerCollaborationRevenueRefund
Namespace Prefix: | ptct_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The entity's share of the income (loss) generated on U.S. sales. + References No definition available. + Details
Name: | ptct_IncomeLossOnU.s.DomesticSalesSharePercentage
Namespace Prefix: | ptct_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition The number of products of the company. + References No definition available. + Details
Name: | ptct_NumberOfProducts
Namespace Prefix: | ptct_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Remaining potential milestones that can be achieved. + References No definition available. + Details
Name: | ptct_RevenueRecognitionMilestonePotentialAchievements
Namespace Prefix: | ptct_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details
Name: | us-gaap_ContractWithCustomerLiabilityCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 + Details
Name: | us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=ptct_CollaborationAndLicenseRevenueMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_RoyaltyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ptct_LicenseAndCollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ptct_NovartisPharmaceuticalsCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ptct_MilestoneAxis=ptct_ResearchAndDevelopmentEventMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ptct_MilestoneAxis=ptct_SalesMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |